EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC

BACKGROUND: The bromodomain and extra-terminal domain (BET) inhibitor is a type of anti-tumor agent, currently being evaluated in phase I and II clinical trials for cancer therapy. It can decrease MYC expression levels and cause effective anti-tumor effects in diverse human cancers. However, its cyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Yalei, Sun, Mingju, Zhan, Xi, Wu, Changqing, Geng, Pengyu, Sun, Xiaoyan, Wu, Yunsong, Zhang, Shuijun, Qin, Jianhua, Zhuang, Zhengping, Liu, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377788/
https://www.ncbi.nlm.nih.gov/pubmed/30770740
http://dx.doi.org/10.1186/s13046-019-1082-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377788/
https://www.ncbi.nlm.nih.gov/pubmed/30770740
http://dx.doi.org/10.1186/s13046-019-1082-6

Ejemplares similares